Achillion announces 100% SVR12 in 6-week and 8-week cohorts in Janssen's phase 2 trial
Achillion announced that expanded safety and efficacy data in a phase 2 study being conducted by Alios BioPharma. The interim results from this phase 2 study confirmed the treatment duration and dose for each component of the triple combination. September 23, 2016